Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
PPP3CB
REST API REST API
Homo sapiens
PPP3CB is differentially expressed in 352 experiments: 160 organism parts: liver, cerebellum, ... (158 more);, 273 disease states: normal, acute myeloid leukemia, ... (271 more);, 109 cell types 452 cell lines 45 compound treatments and 75 other conditions.
Synonyms CNA2, CALNB, CALNA2, PP2Bbeta
Orthologs Ppp3cb (Mus musculus)   CMP2 (Saccharomyces cerevisiae)   CNA1 (Saccharomyces cerevisiae)   F6Y958_CIOIN (Ciona intestinalis)   Ppp3cb (Rattus norvegicus)   E1C2T7_CHICK (Gallus gallus)   A9ZTK8_BOVIN (Bos taurus)   Pp2B-14D (Drosophila melanogaster)   CanA1 (Drosophila melanogaster)   CanA-14F (Drosophila melanogaster)   ppp3cc (Xenopus laevis)   PPP3CB (Canis familiaris)   (Compare orthologs)
Gene Ontology Term protein binding, muscle cell homeostasis, protein complex, dephosphorylation, phosphoprotein phosphatase activity, protein serine/threonine phosphatase activity, insoluble fraction, soluble fraction, calmodulin binding, heart development, protein heterodimerization activity, regulation of gene expression, hydrolase activity, response to cytokine stimulus, response to amphetamine, T cell homeostasis, T cell differentiation, calcium-dependent protein serine/threonine phosphatase activity, negative regulation of T cell mediated cytotoxicity, protein dephosphorylation
InterPro Term Ser/Thr-sp_prot-phosphatase, Metallo_PEstase_dom
UniProt Accession P16298, Q9UMB2, Q5F2F8, Q5F2G0, Q8N1F0, B7Z6P2, E9PBI5, F5H0F8
Search EB-eye ENSG00000107758
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-GEOD-6573, E-GEOD-3526, E-MTAB-62, ... (31 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, E-GEOD-18005, ... (45 experiments)

Factor Value U/D Experiments
MCF-7
1
3
E-GEOD-19639, E-GEOD-20081, E-GEOD-3529, E-GEOD-5823
CCRFCEM
2
E-MTAB-37, E-GEOD-24147
DU145
2
E-GEOD-17482, E-GEOD-20089
HCC1937
2
E-MTAB-37, E-MTAB-62
HCC2157
2
E-MTAB-37, E-MTAB-62
KG1
2
E-MTAB-37, E-GEOD-24147
446 more value(s).


Cell type

studied in E-GEOD-492, E-GEOD-21668, E-GEOD-3920, E-MEXP-750, E-GEOD-20677, ... (57 experiments)

Factor Value U/D Experiments
fibroblast
2
E-GEOD-3204, E-GEOD-3920
macrophage
2
E-GEOD-22373, E-GEOD-360
memory B cell
2
E-MEXP-2360, E-TABM-702
CD4+ T cell
1
2
E-MTAB-24, E-MTAB-25, E-AFMX-5
eNK cell
1
E-GEOD-20499
central memory 1 CD4 T cell
1
E-MEXP-750
103 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-GEOD-1577, E-TABM-15, ... (74 experiments)

Factor Value U/D Experiments
colon carcinoma
3
E-MTAB-37, E-MTAB-62, E-MTAB-57
glioblastoma
3
E-GEOD-4290, E-MEXP-567, E-GEOD-6014
lung adenocarcinoma
1
3
E-MTAB-62, E-MTAB-37, E-GEOD-2514, E-MEXP-231
acute lymphoblastic leukemia
2
E-MTAB-62, E-MTAB-37
acute promyelocytic leukemia
2
E-MTAB-62, E-GEOD-995
adrenocortical carcinoma
2
E-TABM-311, E-GEOD-10927
267 more value(s).


Compound treatment

studied in E-GEOD-697, E-GEOD-3720, E-GEOD-5824, E-TABM-868, E-MEXP-1958, ... (31 experiments)

Factor Value U/D Experiments
none
4
6
E-GEOD-5824, E-MEXP-1958, E-GEOD-697, E-GEOD-412, E-MEXP-1269, ... (10 experiments)
control
2
E-GEOD-5339, E-GEOD-3284
nocodazole
2
E-GEOD-571, E-GEOD-6431
lipopolysaccharide
1
2
E-MEXP-1958, E-GEOD-3720, E-TABM-868
glucose
1
E-MEXP-941
all-trans retinoic acid
1
E-GEOD-995
39 more value(s).


Age at onset

studied in E-GEOD-21521

Factor Value U/D Experiments
not specified
1
1
E-GEOD-21521


Agent
studied in E-GEOD-19519

Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-MTAB-37, E-GEOD-14359

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Classifier
studied in E-GEOD-3493

Clinical history
studied in E-GEOD-22097, E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, E-GEOD-21589, ... (9 experiments)

Clinical info
studied in E-MTAB-37, E-GEOD-6710, E-GEOD-22513, E-MEXP-1251, E-GEOD-19246, ... (9 experiments)

Clinical treatment
studied in E-GEOD-5377, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-1614, E-GEOD-20033, E-MEXP-2359, E-GEOD-6236, E-GEOD-2666, ... (7 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease stage
studied in E-GEOD-7463

Disease staging
studied in E-GEOD-89, E-GEOD-19743, E-GEOD-22544, E-GEOD-7788, E-GEOD-3325, ... (8 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-GEOD-4025, E-MEXP-1482, E-GEOD-7578, E-GEOD-17385, ... (10 experiments)

Genotype
studied in E-MEXP-1996, E-GEOD-2466, E-GEOD-17476, E-GEOD-22593, E-TABM-868, ... (13 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-MEXP-2657, E-GEOD-20540, E-GEOD-22278, E-GEOD-10315, ... (17 experiments)

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276

immunoprecipitated protein
studied in E-GEOD-21918

Individual
studied in E-TABM-325, E-MTAB-197, E-GEOD-2466, E-MEXP-2069, E-GEOD-1926, ... (35 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12108, E-GEOD-12254, E-MEXP-561, ... (9 experiments)

Irradiate
studied in E-TABM-321

Karyotype
studied in E-GEOD-7214

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Material type
studied in E-MEXP-455, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

Phenotype
studied in E-GEOD-19703, E-GEOD-22309, E-GEOD-21750, E-GEOD-17636, E-GEOD-7114 ... (5 experiments)

Population
studied in E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246 ... (5 experiments)

Replicate
studied in E-GEOD-18791, E-GEOD-17204

RNAi
studied in E-MEXP-2115, E-GEOD-12438, E-MEXP-1509, E-GEOD-1676, E-MEXP-101, ... (9 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374, E-GEOD-18995

Sex
studied in E-GEOD-1643, E-GEOD-2466, E-GEOD-7540, E-GEOD-7307, E-GEOD-21521 ... (5 experiments)

Sirna
studied in E-GEOD-21575

Stimulation
studied in E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

Strain or line
studied in E-MEXP-1996

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-33562, E-GEOD-16837, E-GEOD-19246, E-GEOD-19815, E-GEOD-15799, ... (6 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments 00 005
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-3494, E-GEOD-1561, E-GEOD-4922 ... (5 experiments)

Tumor size
studied in E-GEOD-6532

Processing time: 0.502 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM